PTC Therapeutics (PTCT) Competitors $49.87 +0.35 (+0.71%) As of 10:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PTCT vs. TEVA, ITCI, GMAB, RDY, ASND, MRNA, VTRS, QGEN, ROIV, and LNTHShould you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Roivant Sciences (ROIV), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. PTC Therapeutics vs. Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Roivant Sciences Lantheus PTC Therapeutics (NASDAQ:PTCT) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability. Which has preferable earnings & valuation, PTCT or TEVA? PTC Therapeutics has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M4.84-$626.60M-$4.73-10.47Teva Pharmaceutical Industries$16.54B1.07-$1.64B-$1.45-10.78 Does the MarketBeat Community believe in PTCT or TEVA? Teva Pharmaceutical Industries received 766 more outperform votes than PTC Therapeutics when rated by MarketBeat users. Likewise, 67.85% of users gave Teva Pharmaceutical Industries an outperform vote while only 61.96% of users gave PTC Therapeutics an outperform vote. CompanyUnderperformOutperformPTC TherapeuticsOutperform Votes57061.96% Underperform Votes35038.04% Teva Pharmaceutical IndustriesOutperform Votes133667.85% Underperform Votes63332.15% Does the media refer more to PTCT or TEVA? In the previous week, Teva Pharmaceutical Industries had 1 more articles in the media than PTC Therapeutics. MarketBeat recorded 17 mentions for Teva Pharmaceutical Industries and 16 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 1.12 beat Teva Pharmaceutical Industries' score of 0.95 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 10 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is PTCT or TEVA more profitable? Teva Pharmaceutical Industries has a net margin of -9.91% compared to PTC Therapeutics' net margin of -50.32%. Teva Pharmaceutical Industries' return on equity of 42.46% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics-50.32% N/A -16.44% Teva Pharmaceutical Industries -9.91%42.46%6.65% Do insiders and institutionals believe in PTCT or TEVA? 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, PTCT or TEVA? PTC Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Do analysts prefer PTCT or TEVA? PTC Therapeutics presently has a consensus target price of $63.92, indicating a potential upside of 29.09%. Teva Pharmaceutical Industries has a consensus target price of $23.43, indicating a potential upside of 49.85%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 2 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.53Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryTeva Pharmaceutical Industries beats PTC Therapeutics on 12 of the 18 factors compared between the two stocks. Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTCT vs. The Competition Export to ExcelMetricPTC TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.91B$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-8.347.3222.5118.54Price / Sales4.84241.49397.62103.30Price / Cash20.8065.8538.1834.62Price / Book-4.566.486.734.25Net Income-$626.60M$143.41M$3.22B$248.18M7 Day Performance-0.02%2.58%1.38%1.03%1 Month Performance2.38%5.00%2.79%2.70%1 Year Performance47.29%-3.72%15.41%4.05% PTC Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTCTPTC Therapeutics3.9769 of 5 stars$49.87+0.7%$63.92+28.2%+45.0%$3.92B$806.78M-8.371,410Upcoming EarningsAnalyst RevisionNews CoveragePositive NewsTEVATeva Pharmaceutical Industries3.0959 of 5 stars$13.30-2.6%$23.43+76.2%+11.8%$15.08B$16.54B-9.1736,800Upcoming EarningsAnalyst RevisionNews CoveragePositive NewsITCIIntra-Cellular Therapies0.8828 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560Upcoming EarningsAnalyst ForecastGMABGenmab A/S4.4371 of 5 stars$20.07+0.1%$39.17+95.2%-27.2%$13.28B$21.53B11.531,660Upcoming EarningsPositive NewsRDYDr. Reddy's Laboratories1.8412 of 5 stars$13.68+0.1%$17.00+24.3%-6.5%$11.42B$311.31B21.7824,800Upcoming EarningsASNDAscendis Pharma A/S2.3081 of 5 stars$161.15-2.4%$204.67+27.0%+18.8%$9.83B$363.64M-22.70640News CoverageMRNAModerna4.3466 of 5 stars$25.13+1.7%$58.70+133.6%-75.7%$9.72B$3.20B-2.713,900Earnings ReportNews CoverageVTRSViatris1.6837 of 5 stars$7.57+0.1%$10.50+38.7%-27.2%$9.04B$14.74B-10.2337,000Upcoming EarningsQGENQiagen3.8104 of 5 stars$40.51-0.5%$47.83+18.1%+1.4%$9.01B$1.98B112.806,030Upcoming EarningsGap UpROIVRoivant Sciences2.1942 of 5 stars$10.04-1.1%$17.50+74.3%+3.3%$7.16B$122.59M-66.93860Positive NewsLNTHLantheus3.9716 of 5 stars$100.62-0.7%$129.43+28.6%+57.2%$6.89B$1.53B16.74700Upcoming EarningsPositive News Related Companies and Tools Related Companies TEVA Alternatives ITCI Alternatives GMAB Alternatives RDY Alternatives ASND Alternatives MRNA Alternatives VTRS Alternatives QGEN Alternatives ROIV Alternatives LNTH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTCT) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTCT Stock Free PTCT Stock Alerts